Draft policy: Compulsory genetic screening of pregnant women to curb genetic disorders

Published On 2018-08-23 08:10 GMT   |   Update On 2018-08-23 08:10 GMT

New Delhi: The Centre has prepared a draft policy proposing compulsory genetic screening of all pregnant women to prevent inherited disorders such as thalassemia and sickle cell anaemia along with putting in place advanced facilities for the comprehensive care of such patients.


The policy advocates for the provision of medicines, including iron chelating agents, leukocyte filters and infusion pumps free of cost to the poor patients.

In line with 'Make in India' initiative, the draft policy also advocates for the promotion of the manufacture of the equipment and chemicals in the country and "waiver of GST and customs duties to reduce the cost of treatment for the affected families".

Titled "Policy For Prevention and Control of Hemoglobinopathies - Thalassemia, Sickle Cell Disease and variant Hemoglobins In India", the draft note has been put up on the website of the health ministry seeking comments and suggestions from various stakeholders till August 30.

The policy recognises that for prevention, the focus should be on creating awareness of these disorders in the community for better acceptance of carrier screening.

"This is recommended for all pregnant mothers, based on automated red cell counts with confirmation by HPLC analysis for Hb A2 and other haemoglobin variants.

"For women identified to be carriers, their husbands will be screened and in couples where both the partners are carriers, the prenatal diagnosis will be offered to ensure that they have a baby unaffected with a clinically significant hemoglobinopathy," the draft read.

Carrier screening could also be undertaken for high school and college students.

As per the draft policy, all subjects screened would be given a card indicating their status, whether normal, carrier or diseased through systems of colour-coding.

For sickle cell disease, the policy recommended newborn screening to be initiated in areas of high prevalence.

"Thalassemia and sickle cell diseases are two common genetic disorders that are chronic, life-restricting and require long and specialized treatment. They cause severe distress and financial loss to the family and are a great drain on the health resources of the country.

"With the fall in infant mortality rate due to the control of communicable and nutritional disorders in the last decade in India, these disorders have become important causes of morbidity and mortality," the draft policy stated.

According to the draft note, it is estimated that there are almost 3.6 to 3.9 crore carriers of β-thalassemia in India, and about 10,000 to 15,000 babies with β-thalassemia major are born each year.

For sickle cell disease, there are about 25,00,000 carriers of the gene (Hemoglobin AS), and about 1,25,000 patients of sickle cell disease.

The draft policy has proposed creating of centres of excellence in states that will have advanced facilities required for comprehensive care of patients with thalassemia and sickle cell disease, including a bone marrow transplant unit and a prenatal diagnostic centre.

The centres of excellence will provide technical support for thalassemia in medical colleges, tertiary care hospitals, district level health facilities and primary health centres, as well as impart training to the health professionals.

The draft note has recommended the creation of a hemoglobinopathy unit in government medical colleges, tertiary care facilities as well as in district-level hospitals to carry out therapy as well as preventive activities.

It also recommended setting up of a patient registry for thalassemia and sickle cell disease to obtain information on the number of persons affected and the number of carriers to estimate patients who require various services.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News